The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms
Open accessAbstract
Vaccine efficacy (VE) estimates are crucial for assessing the suitability of dengue vaccine candidates for public health implementation, but efficacy trials are subject to a known bias to estimate VE toward the null if heterogeneous exposure is not accounted for in the analysis of trial data. In light of many well-characterized sources of heterogeneity in dengue virus (DENV) transmission, our goal was to estimate the potential magnitude of this bias in VE estimates for a hypothetical dengue vaccine. To ensure that we realistically modeled heterogeneous exposure, we simulated city-wide DENV transmission and vaccine trial protocols using an agent-based model calibrated with entomological and epidemiological data from long-term field studies in Iquitos, Peru. By simulating a vaccine with a true VE of 0.8 in 1,000 replicate trials each designed to attain 90% power, we found that conventional methods underestimated VE by as much as 21% due to heterogeneous exposure. Accounting for the number of exposures in the vaccine and placebo arms eliminated this bias completely, and the more realistic option of including a frailty term to model exposure as a random effect reduced this bias partially. We also discovered a distinct bias in VE estimates away from the null due to lower detectability of primary DENV infections among seronegative individuals in the vaccinated group. This difference in detectability resulted from our assumption that primary infections in vaccinees who are seronegative at baseline resemble secondary infections, which experience a shorter window of detectable viremia due to a quicker immune response. This resulted in an artefactual finding that VE estimates for the seronegative group were approximately 1% greater than for the seropositive group. Simulation models of vaccine trials that account for these factors can be used to anticipate the extent of bias in field trials and to aid in their interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037 · cited 1×
“An estimated 390 million people worldwide experience dengue virus (DENV) infections each year, with approximately 96 million of those showing clinically apparent symptoms [1].”
Self-citationWoolhouse, M. E. J., Dye, C., Etard, J.-F., Smith, T., Charlwood, J. D., Garnett, G. P., Hagan, P., Hii, J. L. K., Ndhlovu, P. D., Quinnell, R. J., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.338 · Cited by 1,194
The global burden of dengue: an analysis from the Global Burden of Disease Study 2013
Stanaway, J. D., Shepard, D. S., Undurraga, E. A., Halasa, Y. A., Coffeng, L. E., Brady, O. J., Hay, S. I., Bedi, N., Bensenor, I. M., Castañeda-Orjuela, C. A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00026-8 · Cited by 1,124
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
Hadinegoro, S. R., Arredondo-García, J. L., Capeding, M. R., Deseda, C., Chotpitayasunondh, T., Dietze, R., Hj Muhammad Ismail, H. I., Reynales, H., Limkittikul, K., Rivera-Medina, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506223 · Cited by 1,077
Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61060-6 · Cited by 973
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Villar, L., Dayan, G. H., Arredondo-García, J. L., Rivera, D. M., Cunha, R., Deseda, C., Reynales, H., Costa, M. S., Morales-Ramírez, J. O., Carrasquilla, G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411037 · Cited by 942
Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T. A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61428-7 · Cited by 818
The Incubation Periods of Dengue Viruses
Chan, M., & Johansson, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050972 · Cited by 673
DISPERSAL OF THE DENGUE VECTOR AEDES AEGYPTI WITHIN AND BETWEEN RURAL COMMUNITIES
HARRINGTON, L. C., SCOTT, T. W., LERDTHUSNEE, K., COLEMAN, R. C., COSTERO, A., CLARK, G. G., JONES, J. J., KITTHAWEE, S., KITTAYAPONG, P., SITHIPRASASNA, R., et al. (2005) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.72.209 · Cited by 619
Self-citation
Cited by
Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., Salati, M., Dottorini, L., Iaculli, A., Varricchio, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3520 · Cited by 530
DeepSTARR predicts enhancer activity from DNA sequence and enables the de novo design of enhancers
de Almeida, B. P., Reiter, F., Pagani, M., & Stark, A. (2021) · doi:10.1101/2021.10.05.463203 · Cited by 284
de Almeida, B. P., Reiter, F., Pagani, M., & Stark, A. (2022) · Nature Genetics · doi:10.1038/s41588-022-01048-5 · Cited by 283
Bijlsma, A., Omrani, A., Spoelder, M., Verharen, J. P. H., Bauer, L., Cornelis, C., de Zwart, B., van Dorland, R., Vanderschuren, L. J. M. J., & Wierenga, C. J. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.0524-22.2022 · Cited by 61
Quantitative fragmentomics allow affinity mapping of interactomes
Gogl, G., Zambo, B., Kostmann, C., Cousido-Siah, A., Morlet, B., Durbesson, F., Negroni, L., Eberling, P., Jané, P., Nominé, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33018-0 · Cited by 51
Metadata
- Authors
- España, G., Hogea, C., Guignard, A., ten Bosch, Q. A., Morrison, A. C., Smith, D. L., Scott, T. W., Schmidt, A., & Perkins, T. A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-01-25
- Volume
- 14
- Issue
- 1
- Pages
- e0210041
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2912652602
- Cited by
- 744
- References
- 69
- FWCI
- 91.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms. https://app.cochat.ai/papers/10.1371/journal.pone.0210041
- The paper
- España, G., Hogea, C., Guignard, A., ten Bosch, Q. A., Morrison, A. C., Smith, D. L., Scott, T. W., Schmidt, A., & Perkins, T. A. (2019). Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms. PLOS ONE. https://doi.org/10.1371/journal.pone.0210041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
